ASTRAZENECA AND BRISTOL-MYERS SQUIBB COMPLETE EXPANSION OF DIABETES ALLIANCE THROUGH BRISTOL-MYERS SQUIBB’S ACQUISITION OF AMYLIN PHARMACEUTICALS
9 August 2012
AstraZeneca and Bristol-Myers Squibb today announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb. As previously disclosed, the payment is being made in connection w
